ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ascendis Pharma A/S
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Feb 11, 2026
$229.95+4.70 (+2.09%)
Close on Oct 19, 2026
Ascendis Pharma A/S income statement
Ratios
Latest available, balances at Dec 31, 2025
Profitability, TTM
- Gross margin
- 86.8%
- Operating margin
- -18.9%
- Net margin
- -31.7%
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 1.04
- Debt to equity
- –
- Debt to assets
- 62.5%
- Cash to current liabilities
- 57.6%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
Valuation ratios need the share price and fill in once daily prices are connected.